These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 33412958)

  • 1. The impact of pharmaceutical innovation on the longevity and hospitalization of New Zealand cancer patients, 1998-2017.
    Lichtenberg FR
    Expert Rev Pharmacoecon Outcomes Res; 2021 Jun; 21(3):476-477. PubMed ID: 33412958
    [TBL] [Abstract][Full Text] [Related]  

  • 2. How cost-effective are new cancer drugs in the U.S.?
    Lichtenberg FR
    Expert Rev Pharmacoecon Outcomes Res; 2020 Feb; 20(1):39-55. PubMed ID: 31906739
    [No Abstract]   [Full Text] [Related]  

  • 3. The impact of pharmaceutical innovation on premature cancer mortality in Switzerland, 1995-2012.
    Lichtenberg FR
    Eur J Health Econ; 2016 Sep; 17(7):833-54. PubMed ID: 26342826
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of pharmaceutical innovation on premature mortality, cancer mortality, and hospitalization in Slovenia, 1997-2010.
    Lichtenberg FR
    Appl Health Econ Health Policy; 2015 Apr; 13(2):207-22. PubMed ID: 25564200
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact of pharmaceutical innovation on premature cancer mortality in Canada, 2000-2011.
    Lichtenberg FR
    Int J Health Econ Manag; 2015 Sep; 15(3):339-359. PubMed ID: 27878681
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of pharmaceutical innovation on longevity, hospitalization and medical expenditure in Turkey, 1999-2010.
    Lichtenberg FR; Tatar M; Çalışkan Z
    Health Policy; 2014 Sep; 117(3):361-73. PubMed ID: 24996837
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of pharmaceutical innovation on longevity: Evidence from the U.S. and 26 high-income countries.
    Lichtenberg FR
    Econ Hum Biol; 2022 Aug; 46():101124. PubMed ID: 35344806
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmaceutical innovation and the longevity of Australians: a first look.
    Lichtenberg FR; Duflos G
    Adv Health Econ Health Serv Res; 2008; 19():95-117. PubMed ID: 19548515
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The impact of pharmaceutical innovation on longevity and medical expenditure in France, 2000-2009.
    Lichtenberg FR
    Econ Hum Biol; 2014 Mar; 13():107-27. PubMed ID: 23664114
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact of pharmaceutical innovation on the burden of disease in Canada, 2000-2016.
    Lichtenberg FR
    SSM Popul Health; 2019 Aug; 8():100457. PubMed ID: 31440578
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trends in the Price per Median and Mean Life-Year Gained Among Newly Approved Cancer Therapies 1995 to 2017.
    Chen AJ; Hu X; Conti RM; Jena AB; Goldman DP
    Value Health; 2019 Dec; 22(12):1387-1395. PubMed ID: 31806195
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Impact of Pharmaceutical Innovation on Cancer Mortality in Belgium, 2004-2012.
    Lichtenberg FR
    Forum Health Econ Policy; 2016 Sep; 20(1):. PubMed ID: 31419903
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The impact of recent chemotherapy innovation on the longevity of myeloma patients: US and international evidence.
    Hostenkamp G; Lichtenberg FR
    Soc Sci Med; 2015 Apr; 130():162-71. PubMed ID: 25703669
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Impact of New Drug Launches on Hospitalization in 2015 for 67 Medical Conditions in 15 OECD Countries: A Two-Way Fixed-Effects Analysis.
    Lichtenberg FR
    Forum Health Econ Policy; 2019 Apr; 21(2):. PubMed ID: 31017868
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New Cancer Drug Approvals From the Perspective of a Universal Healthcare System: Analyses of the Pan-Canadian Oncology Drug Review Recommendations.
    Niraula S; Nugent Z
    J Natl Compr Canc Netw; 2018 Dec; 16(12):1460-1466. PubMed ID: 30545993
    [No Abstract]   [Full Text] [Related]  

  • 16. The impact of pharmaceutical innovation on the burden of disease in Ireland, 2000-2015.
    Lichtenberg FR
    J Public Health (Oxf); 2020 Nov; 42(4):816-827. PubMed ID: 31927585
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of therapeutic procedure innovation on hospital patient longevity: evidence from Western Australia, 2000-2007.
    Lichtenberg FR
    Soc Sci Med; 2013 Jan; 77():50-9. PubMed ID: 23206558
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The cost effectiveness of genetic testing for CYP2C19 variants to guide thienopyridine treatment in patients with acute coronary syndromes: a New Zealand evaluation.
    Panattoni L; Brown PM; Te Ao B; Webster M; Gladding P
    Pharmacoeconomics; 2012 Nov; 30(11):1067-84. PubMed ID: 22974536
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cholesterol-lowering therapy with pravastatin in patients with average cholesterol levels and established ischaemic heart disease: is it cost-effective?
    Glasziou PP; Eckermann SD; Mulray SE; Simes RJ; Martin AJ; Kirby AC; Hall JP; Caleo S; White HD; Tonkin AM
    Med J Aust; 2002 Oct; 177(8):428-34. PubMed ID: 12381252
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative effectiveness of long-acting risperidone in New Zealand: a report of resource utilization and costs in a 12-month mirror-image analysis.
    Carswell C; Wheeler A; Vanderpyl J; Robinson E
    Clin Drug Investig; 2010; 30(11):777-87. PubMed ID: 20712387
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.